Clinical Trials Logo

Leptomeningeal Metastases clinical trials

View clinical trials related to Leptomeningeal Metastases.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05184816 Recruiting - Clinical trials for Leptomeningeal Metastases

A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis

Start date: December 22, 2021
Phase: Phase 1
Study type: Interventional

The researchers are doing this study to find out whether deferoxamine (DFO) given intrathecally (directly into the CSF) is a safe treatment for people with leptomeningeal metastasis from solid tumor cancer. The researchers will test different doses of DFO to find the highest dose that causes few or mild side effects. When the dose is found, they will test it in future participants to see whether DFO is a safe and effective treatment for people with leptomeningeal metastasis from non-small cell lung cancer (NSCLC). They are also doing this study to see how the body absorbs, distributes, gets rid of, and responds to DFO.